Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Herbert Kotz"'
Autor:
Jeffrey Schlom, William L. Dahut, Herbert Kotz, Seth M. Steinberg, James W. Hodge, Jack P. Higgins, Mary P. Pazdur, Jacquin L. Jones, Vittore Cereda, Cinzia Remondo, Diane J. Poole, Claudia Palena, Junko Yokokawa, Kwong-Yok Tsang, Philip M. Arlen, James L. Gulley
Supplementary Data from Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52c8af7ecc80a59b46abf061226ce87d
https://doi.org/10.1158/1078-0432.22439665
https://doi.org/10.1158/1078-0432.22439665
Autor:
Elise C. Kohn, Seth M. Steinberg, Daniel Kimm, Peter Choyke, Katherine Calvo, Bradford J. Wood, Herbert Kotz, Minshu Yu, Lori Minasian, Amanda J. Walker, Christina M. Annunziata
Supplementary Data from Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f495c50fcef64909e21849d84970a65
https://doi.org/10.1158/1078-0432.22440550.v1
https://doi.org/10.1158/1078-0432.22440550.v1
Autor:
Elise C. Kohn, Seth M. Steinberg, Daniel Kimm, Peter Choyke, Katherine Calvo, Bradford J. Wood, Herbert Kotz, Minshu Yu, Lori Minasian, Amanda J. Walker, Christina M. Annunziata
Purpose: To evaluate clinical activity and target modulation of vandetanib in women with recurrent ovarian cancer.Experimental Design: A phase II trial of orally administered vandetanib 300 mg daily was designed to include analyses of target inhibiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36fe95d95d40eb061b7d8b1fd8569e75
https://doi.org/10.1158/1078-0432.c.6517867
https://doi.org/10.1158/1078-0432.c.6517867
Autor:
Jeffrey Schlom, William L. Dahut, Herbert Kotz, Seth M. Steinberg, James W. Hodge, Jack P. Higgins, Mary P. Pazdur, Jacquin L. Jones, Vittore Cereda, Cinzia Remondo, Diane J. Poole, Claudia Palena, Junko Yokokawa, Kwong-Yok Tsang, Philip M. Arlen, James L. Gulley
Purpose: Poxviral vectors have a proven safety record and can be used to incorporate multiple transgenes. Prior clinical trials with poxviral vaccines have shown that immunologic tolerance to self-antigens can be broken. Carcinoembryonic antigen (CEA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7595bd0013f69f6f354aaba2b0cfaa92
https://doi.org/10.1158/1078-0432.c.6517102
https://doi.org/10.1158/1078-0432.c.6517102
Autor:
Arfan Shahzad, Mohd Syarol Azuan bin Zakaria, Herbert Kotzab, Muhammad Abdul Majid Makki, Aamir Hussain, Julia Fischer
Publikováno v:
Humanities & Social Sciences Communications, Vol 10, Iss 1, Pp 1-14 (2023)
Abstract Using Industrial Revolution 4.0 (IR4.0) technology, companies can upscale their innovation in organizing, managing, and controlling the value chain life cycle. IR4.0 is anticipated to bring challenges and opportunities to developing economie
Externí odkaz:
https://doaj.org/article/1dfe381dad804875898b22892cc39e0a
Autor:
William L. Dahut, Nehal J. Lakhani, James L. Gulley, Philip M. Arlen, Elise C. Kohn, Herbert Kotz, Debbie McNally, Allyson Parr, Diana Nguyen, Sherry X. Yang, Seth M. Steinberg, Jürgen Venitz, Alex Sparreboom, William Figg, II
Publikováno v:
Cancer Biology & Therapy. 5:22-27
Purpose: To determine the maximum-tolerated dose (MTD) and toxicity profile of the novel anticancer agent, 2-methoxyestradiol (2ME2) administered orally, in patients with solid tumors. Materials and methods: Twenty patients with refractory solid tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21b135aef85e065ace19862f252e4632
https://doi.org/10.4161/cbt.5.1.2349
https://doi.org/10.4161/cbt.5.1.2349
Publikováno v:
Oncogene. 20:7694-7698
Human ovarian cancer cells and tissues were examined for the presence or absence of a 42-bp splicing variant of ERCC1 gene, and for a possible functional role of this 42-bp sequence. This specific sequence exists in exon I, the 5'-UTR of the gene. Lo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd71ed74cdb7e4179061b163b3836e0d
https://doi.org/10.1038/sj.onc.1204977
https://doi.org/10.1038/sj.onc.1204977